CD25是独立于染色体核型的AML预后不良因素

Expression of CD25 in Acute Myeloid Leukemia Is An Adverse Prognostic Factor Independent of the Chromosome Karyotype

目的:探讨CD25在急性髓系白血病(AML)中的表达及其意义。方法:收集168例新诊断AML(非APL)患者的临床资料。回顾性分析CD25在AML中的表达及其临床特征。结果:168例中29例(17.26%)患者白血病细胞表达CD25抗原。CD25^+AM L患者多发生在高危及正常核型中,伴初诊时相对较高的WBC及Plt计数、外周血和骨髓原始细胞比例增高。与CD25^-AM L患者相比,CD25^+AM L患者CR率低,1个疗程CR率分别为49.02%和16.00%(P<0.05),2个疗程CR率分别74.60%和为46.67%(P<0.05),OS时间明显缩短(P<0.05)。CD25^+AM L患者高危核型组与中危核型组比较,OS差异无统计学意义。结论:伴有CD25表达的AM L有一定的临床特征,是独立于染色体核型的危险因素,患者完全缓解率低、生存期短。

Objective:To investigate the CD25 expression in patients with acute myeloid leukemia(AML) and its significance.Methods:Clinical data of 168 newly diagnosed AML patients(except APL) were collected.The expression of CD25 in AML patients and its clinical characteristics were retrospectively analyzed.Results:The leukemia cells of 29 out of 168 cases(17.26%) expressed CD25 antigen.Most of CD25 positive AML patients were occurred in patients with unfavourable or normal karyotype,higher WBC and Plt count at diagnosis and higher percentage of blasts in peripheral blood and bone marrow.Compared with CD25 AML patients,CD25^+ AML patients had lower CR rate(the CR rate of 1course of treatment were 49.02%and 16.00%,respectively,P < 0.05,the CR rate of 2 courses of treatment were 74.60%and 46.67%,respectively,P < 0.05),and the OS time of CD25^+ AML patients were obviously shorter(P <0.05).The OS in CD25^+ AML patients with unfavorable karyotype were not significantly different from that in patients with intermediate karyotype(P <0.05).Conclusion:The CD25^+ AML patients have some typical clinical features,and the expression of CD25 in AML is an risk factor independent of the chromosome karyotype in terms of low complete remission rate and short survival time.